科研之友
微信
新浪微博
Facebook
分享链接
摘要
The increasing incidence and prevalence of multi-drug resistance (MDR) among contemporary Gram-negative bacteria represents a significant threat to human health. Since their discovery, beta-lactam antibiotics have been a major component of the armamentarium against these serious pathogens. Unfortunately, a wide range of beta-lactamase enzymes have emerged that are capable of inactivating these powerful drugs. In the past 30 years, a major advancement in the battle against microbes has been the development of beta-lactamase inhibitors, which restore the efficacy of beta-lactam antibiotics (e.g., ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin/clavulanate, and piperacillin/tazobactam). Unfortunately, many newly discovered beta-lactamases are not inactivated by currently available inhibitors. Is there hope? For the first time in many years, we can anticipate the development and introduction into clinical practice of novel inhibitors. Although these inhibitors may still not be effective for all beta-lactamases, their introduction is still welcome. This review focuses on the novel beta-lactamase inhibitors that are closest to being introduced in the clinic.
- 出版日期2013-12-24
